TriangleLinvoseltamab (NCT06376526)
Linvoseltamab trial for Multiple Myeloma (NCT06376526). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed multiple myeloma that still has residual disease after initial combination therapy. At least a partial response after four cycles is usually required.
The idea: linvoseltamab links BCMA on myeloma cells to CD3 on T cells. Intravenous doses increase gradually before treatment. Patients receive four 28-day cycles; those still MRD-positive receive two more. Researchers test whether marrow residual disease becomes undetectable. Previous stem-cell transplantation is excluded.
This phase 2 study plans 150 patients. Dickran Kazandjian leads at the University of Miami, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.